The COVID-19 has had a minor impact on the pulmonary arterial hypertension market, and the lingering consequences of the coronavirus pandemic may persist in the coming years. The industry's response to the coronavirus outbreak peaked in early 2020, when pulmonary arterial hypertension patients were at a higher risk of contracting the virus. Other obstacles to the industry's growth included delays in diagnostic testing, revised hospital and emergency care protocols, and a disrupted drug supply chain, to name a few. As a result of the rising number of hospitalised PAH-COVID-19 patients, the pandemic has highlighted the need of PAH medications.
Read More: https://bloggerstrive.blogspot.com/2022/02/pulmonary-arterial-hypertension-market.html
Click here for Pulmonary Arterial Hypertension Market Report: https://www.coherentmarketinsights.com/market-insight/pulmonary-arterial-hypertension-pah-market-203
Comments
0 comment